Concord Biotech

Concord Biotech

1,657.70
+22.20
(1.36%)
Market Cap
17,342.23 Cr
EPS
35.52
PE Ratio
48.06
Dividend Yield
0.53 %
Industry
Healthcare
52 Week High
2,664.00
52 Week Low
1,345.00
PB Ratio
9.44
Debt to Equity
0.00
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from4 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+50.00 %
+50.00 %
Hold
Hold+50.00 %
+50.00 %
Sell
Sell0.0 %
0.0 %

Company News

View All News
Caret
positive
Concord Biotech announced the completion of an EU GMP (Good Manufacturing Practice) inspection at its API (Active Pharmaceutical Ingredient) facility located in Limbassi. The inspection process has been concluded at this manufacturing site.
neutral
Concord Biotech Limited reported quarterly revenues of INR 204 crores compared to INR 216 crores in the same period last year, representing a 5% decline. The API business segment saw a 10% decline to INR 153.8 crores, while formulation business grew 12% to INR 50.2 crores. EBITDA dropped to INR 61 crores from INR 81 crores, with margins at 30.1% versus 37.7% previously. The company attributed the revenue decline primarily to customer procurement pattern lumpiness, noting that the preceding quarter had exceptionally high sales. EBITDA margins were impacted by commercialization costs of approximately INR 12-13 crores from the new injectable facility in Valthera. Excluding these costs, EBITDA margins stood at approximately 37%, consistent with the same quarter last year. The company received US FDA approval for teriflunomide tablets and successfully passed multiple regulatory inspections including US FDA, European GMP, and Russian GMP. Concord incorporated two new subsidiaries: Stellon Biotech Inc. for US market operations and Concord Lifegen Limited for domestic marketing. The company initiated CDMO business sales to the US market and launched two products from its injectable facility in the domestic market. Management expects the injectable facility costs to normalize as revenues scale up through FY26.
neutral
Concord Biotech Limited published its Q1FY26 financial results showing revenue of Rs 204 crores, down 5% from Rs 216 crores in Q1FY25, attributed to lumpiness in customer procurement patterns. EBITDA declined 24% to Rs 61 crores with margins at 30.1% compared to 37.7% in the previous year, impacted by expenses related to commercialization of new injectable facility at Valthera. PAT decreased 26% to Rs 44 crores. The company commenced commercial supply of CDMO services to a US customer in Q2FY26 and successfully completed regulatory inspections by USFDA, EU GMP, and Russian GMP at its Dholka facility. Concord acquired 75% stake in US-based Stellon Biotech and incorporated wholly-owned subsidiary Concord Lifegen Limited for domestic market operations. The company maintains optimism for FY26 growth trajectory despite quarterly volatility.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,648.60
#1 3,95,554.36
33.89
#1 54,729.00
9.71
#1 10,980
-19.84
52.26
6,112.00
1,62,254.40
69.65
9,712.00
18.67
2,191
26.74
43.25
1,578.20
1,27,472.45
23.36
28,409.50
7.12
5,291
9.88
51.20
3,567.40
1,20,737.03
59.39
11,539.40
6.99
1,911
19.91
45.02
1,322.70
1,10,388.72
19.26
33,741.20
16.73
5,725
1.26
60.34
2,638.30
1,06,079.50
56.09
12,744.20
#1 20.90
2,007
-18.14
53.18
1,047.85
1,05,438.23
22.34
23,511.00
18.55
4,615
2.60
62.48
2,046.60
93,467.29
25.08
22,909.50
13.74
3,306
#1 51.64
62.82
30,890.00
65,639.09
45.28
6,684.70
9.64
1,414
11.55
39.70
1,128.90
65,566.70
#1 18.94
32,345.60
9.43
3,484
-10.24
57.66
Forecast
Actual
Growth Rate
Revenue Growth
18.26 %
Net Income Growth
28.32 %
Cash Flow Change
-7.89 %
ROE
8.44 %
ROCE
7.81 %
EBITDA Margin (Avg.)
3.94 %

Quarterly Financial Results

Quarterly Financials
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
195
165
250
285
208
271
252
330
228
320
261
439
219
Expenses
116
122
131
146
123
147
135
187
135
177
146
241
143
EBITDA
79
44
119
139
85
124
117
143
93
144
115
198
77
Operating Profit %
36 %
24 %
46 %
47 %
37 %
44 %
44 %
41 %
38 %
43 %
40 %
44 %
30 %
Depreciation
14
13
14
14
13
13
14
14
13
13
13
15
18
Interest
1
1
1
2
1
1
1
1
0
0
0
0
0
Profit Before Tax
64
30
105
124
71
110
103
129
80
130
101
184
59
Tax
15
8
27
32
17
29
26
34
20
35
25
43
15
Net Profit
49
22
77
92
55
81
78
95
60
96
76
140
44
EPS in ₹
4.71
2.10
7.40
8.75
5.21
7.74
7.41
9.08
5.70
9.15
7.26
13.42
4.21

Balance Sheet

Balance Sheet
2020
2022
2023
2024
2025
Total Assets
941
1,313
1,514
1,701
2,034
Fixed Assets
240
573
593
575
795
Current Assets
539
633
728
896
1,135
Capital Work in Progress
141
74
173
212
51
Investments
199
74
137
246
335
Other Assets
361
592
611
668
854
Total Liabilities
941
1,313
1,514
1,701
2,034
Current Liabilities
115
155
192
142
184
Non Current Liabilities
55
54
32
32
38
Total Equity
770
1,103
1,290
1,527
1,813
Reserve & Surplus
761
1,094
1,280
1,516
1,802
Share Capital
10
10
11
11
11

Cash Flow

Cash Flow
2020
2021
2022
2023
2024
2025
Net Cash Flow
-1
3
-5
3
12
-14
Investing Activities
-114
-195
-112
-158
-155
-160
Operating Activities
155
167
208
246
266
245
Financing Activities
-43
31
-100
-85
-99
-99

Share Holding

% Holding
Aug 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
44.08 %
44.08 %
44.08 %
44.08 %
44.08 %
44.08 %
44.08 %
44.08 %
44.08 %
FIIs
0.00 %
7.30 %
0.00 %
6.48 %
7.11 %
8.10 %
8.33 %
9.35 %
9.11 %
DIIs
4.89 %
8.18 %
8.13 %
8.46 %
10.40 %
9.89 %
9.66 %
9.16 %
8.87 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
13.33 %
6.78 %
6.76 %
7.08 %
7.64 %
7.33 %
7.33 %
6.94 %
7.43 %
Others
37.69 %
33.66 %
41.03 %
33.90 %
30.76 %
30.61 %
30.59 %
30.47 %
30.51 %
No of Share Holders
3,77,572
1,00,927
87,486
83,296
80,737
84,298
82,004
81,219
82,045

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.83 8.75 10.7
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.45 0.52 0.65

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
22 Jun 2024 DIVIDEND Dividend
₹ 8.75 /share
21 Jun 2024 1,460.10 1,559.25
29 Jun 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
29 Jun 2024 1,460.10 1,549.05
11 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
11 Nov 2024 1,812.25 1,850.00
13 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Feb 2025 2,125.70 2,119.00
29 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
29 May 2025 1,532.10 1,635.70
08 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
08 Aug 2025 1,739.70 1,633.10
03 Sept 2025 DIVIDEND Dividend
₹ 10.70 /share
03 Sept 2025 1,635.70 1,691.15
09 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
09 Sept 2025 1,648.30 1,610.20

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
Shareholder Meeting / Postal Ballot-Scrutinizers Report7 days ago
Shareholder Meeting / Postal Ballot-Outcome of AGM9 days ago
Successful Completion Of EU GMP InspectionAug 21, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 18, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Business Responsibility and Sustainability Reporting (BRSR)Aug 13, 2025
Reg. 34 (1) Annual Report.Aug 13, 2025
Intimation Of 40Th Annual General Meeting NoticeAug 13, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 11, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 10, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 10, 2025
Financial Results Q1 FY 2025-2026Aug 08, 2025
Record DateAug 08, 2025
Board Meeting Outcome for Outcome Of Board MeetingAug 08, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 05, 2025
Board Meeting Intimation for Approval Of Standalone And Consolidated Unaudited Financial Results For The First Quarter Ended On June 30 2025 Along With Limited Review ReportAug 04, 2025
Successful Completion Of Russian GMP InspectionJul 26, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJul 22, 2025
Successful Completion Of EU GMP InspectionJul 18, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 08, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJul 02, 2025
Closure of Trading WindowJun 25, 2025
Update On The USFDA Inspection At The Companys API Facility At DholkaJun 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJun 06, 2025
Intimation Pursuant To Regulation 30(5) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Jun 02, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 02, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 02, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 31, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 30, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 30, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 29, 2025
Appointment Of AuditorsMay 29, 2025
Appointment of Company Secretary and Compliance OfficerMay 29, 2025
Corporate Action-Board approves DividendMay 29, 2025
Financial ResultMay 29, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On 29Th May2025May 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 26, 2025
Board Meeting Intimation for Approval Of Audited Financial Statements For The Quarter And Year Ended March 31 2025.May 23, 2025
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerMay 13, 2025
Completion Of Inspection By United States Food And Drug Administration (USFDA) Of Our API Facility At Dholka.May 02, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 09, 2025
Disclosure Under Of SEBI (LODR) Regulations 2015 Concord Biotech Secures Abbreviated New Drug Application (ANDA) Approval To Market Teriflunomide Tablets 7 Mg And 14 Mg In The USApr 08, 2025
Commencement Of Commercial Production At Unit-4 ValtheraMar 25, 2025
Closure of Trading WindowMar 22, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 10, 2025

Technical Indicators

RSI(14)
Neutral
44.16
ATR(14)
Less Volatile
56.00
STOCH(9,6)
Neutral
47.12
STOCH RSI(14)
Overbought
81.28
MACD(12,26)
Bullish
0.92
ADX(14)
Weak Trend
11.89
UO(9)
Bearish
46.75
ROC(12)
Downtrend And Accelerating
-2.99
WillR(14)
Neutral
-60.50

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Quant Healthcare Fund Direct - Growth
3.66%
83472
3.66%
3.66%
UTI Small Cap Fund Direct - Growth
0.00%
-80629
-0.30%
-0.59%
SBI Healthcare Opportunities Fund Direct Plan-Growth
3.06%
71000
0.21%
0.67%
Invesco India ELSS Tax Saver Fund Direct-Growth
0.51%
-51773
-0.34%
-0.35%
Union Midcap Fund Direct - Growth
0.00%
-43925
-0.52%
-0.62%
Baroda BNP Paribas Large & Mid Cap Fund Direct - Growth
1.47%
-40000
-0.49%
-0.54%
Motilal Oswal Quant Fund Direct-Growth
0.00%
-7724
-0.94%
-0.96%
DSP Small Cap Direct Plan-Growth
0.01%
6464
0.01%
0.01%
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth
0.29%
1563
0.29%
0.29%
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
0.30%
1201
0.00%
0.00%
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth
0.30%
533
0.00%
0.00%
SBI Nifty Smallcap 250 Index Fund Direct - Growth
0.30%
472
0.00%
0.00%
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
0.29%
366
-0.01%
-0.01%
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth
0.30%
282
0.00%
0.00%
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth
0.29%
191
-0.01%
-0.01%
Nippon India Nifty 500 Equal Weight Index Fund Direct-Growth
0.19%
-161
-0.01%
-0.01%
Motilal Oswal Nifty 500 Index Fund Direct - Growth
0.03%
82
0.00%
0.00%
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth
0.30%
58
0.00%
0.00%
Kotak Nifty Smallcap 250 Index Fund Direct-Growth
0.29%
51
-0.01%
-0.01%
Groww Nifty Smallcap 250 Index Fund Direct - Growth
0.30%
32
-0.01%
-0.01%
Axis Nifty 500 Index Fund Direct-Growth
0.03%
25
0.00%
0.00%
HDFC Nifty500 Multicap 50:25:25 Index Fund Direct-Growth
0.07%
-21
0.00%
0.00%
Groww Nifty Total Market Index Fund Direct - Growth
0.03%
9
0.00%
0.00%
SBI Nifty 500 Index Fund Direct-Growth
0.03%
8
0.00%
0.00%
Angel One Nifty Total Market Index Fund Direct - Growth
0.03%
5
0.00%
0.00%

About Concord Biotech

Concord Biotech Limited is an India-based biopharma company that develops and manufactures fermentation-based APIs and formulations. It focuses on immunosuppressants, oncology, anti-infectives, nephrology, and critical care. The company operates three manufacturing facilities in Gujarat, India, with a total annual installed fermentation capacity of 1,250 m3 for APIs. Concord Biotech supplies products to over 70 countries, including regulated markets like the United States, Europe, and Japan. The company was originally incorporated in 1984, acquired by Sudhir Vaid in 2000, and launched its formulation business in 2016. It went public in August 2023 through an Initial Public Offer.
Listing Date
18 Aug, 2023(2 Years, 1 days)
Chairperson NameSUDHIR JAIRAM VAID